Kevin D'Amour
Keine laufenden Positionen mehr
Vermögen: 1 378 $ am 31.03.2024
Profil
Kevin A.
D'Amour worked as a Research Associate at Gen-Probe, Inc. and as the Chief Scientific Officer & Vice President-Research at ViaCyte, Inc. from 2012 to 2021.
He then worked as the Chief Scientific Officer at Eterna Therapeutics, Inc. from 2021 to 2022.
D'Amour holds a doctorate degree from the University of California San Diego and an undergraduate degree from the University of New Hampshire.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ETERNA THERAPEUTICS INC.
0,01% | 26.04.2023 | 574 ( 0,01% ) | 1 378 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Kevin D'Amour
| Unternehmen | Position | Ende |
|---|---|---|
| ETERNA THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 26.08.2022 |
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 25.06.2021 |
Gen-Probe, Inc.
 Gen-Probe, Inc. Medical SpecialtiesHealth Technology Gen-Probe, Inc. develops, manufactures and markets rapid, accurate and molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. It also develops and manufactures the PROCLEIX assays, which are used to detect human immunodeficiency virus, the hepatitis C virus, the hepatitis B virus, and the West Nile virus in donated human blood. The firm's clinical diagnostics products include APTIMA family of assays, which are used to detect the common STDs chlamydia and gonorrhea. Gen-Probe was founded by Thomas H. Adams and David E. Kohne in 1983 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Ausbildung von Kevin D'Amour
| University of California San Diego | Doctorate Degree |
| University of New Hampshire | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ETERNA THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Gen-Probe, Inc.
Gen-Probe, Inc. Medical SpecialtiesHealth Technology Gen-Probe, Inc. develops, manufactures and markets rapid, accurate and molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. It also develops and manufactures the PROCLEIX assays, which are used to detect human immunodeficiency virus, the hepatitis C virus, the hepatitis B virus, and the West Nile virus in donated human blood. The firm's clinical diagnostics products include APTIMA family of assays, which are used to detect the common STDs chlamydia and gonorrhea. Gen-Probe was founded by Thomas H. Adams and David E. Kohne in 1983 and is headquartered in San Diego, CA. | Health Technology |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
